Innogen · People · Innogen Associates
Dr Pauline Gleadle

Research Associate

Pauline.gleadle@gmail.com

Pauline has degrees in economics (Cambridge), psychology (Open University and LSE) and a PhD in management control (Brunel) as well as being a Chartered Accountant. She has worked full-time at Cranfield School of Management, the Open University and the University of East Anglia (London campus) as well as at many other institutions on a part-time basis. Currently, she is engaged in post-doctoral research mentoring at the University of Westminster on a range of topics including corporate governance in both the UK and in developing countries.

Her current research focuses on the sustainability of different business models, particularly those of the pharmaceutical and biotech industries under conditions of financialization, where financial markets act dynamically to affect the strategy and governance of firms. To date, she has published on the pharmaceutical and biotech industries in the UK and in Poland and is developing this work to explore the sectors in the US and France, work in which she collaborates with overseas colleagues. Her international research is informed by the comparative capitalisms literature.

SELECTED PUBLICATIONS

‘Restructuring and innovation in pharmaceuticals and biotechs: the impact of financialisation,’ (with Stuart Parris, Alan Shipman & Roberto Simonetti), (2014). Critical Perspectives on Accounting, 25,1, 67-77.

‘Critical accounts and perspectives on financialisation,’ (with Colin Haslam and Ya Ping Yin), (2014), Critical Perspectives on Accounting, (2014), 25, 1, 1-4.

‘The role of institutional context in the development of the SME biotech sector in Poland,’ (with Greg Micek & Piotr Dawidko), (2014), 25, 132-150. Studies of the Industrial Geography Commission’ of the Polish Geographical Society.

‘”The ground beneath my feet”: projects, project management and the intensified control of R&D engineers,’ (with Damian Hodgson and John Storey), (2012), New Technology, Work and Employment, 27, 3, 163-177.

‘Bio-pharma: A financialized business model’,(with T Andersson, C Haslam & N Tsitsianis), (2010), Critical Perspectives on Accounting, 21,7, 631-641.

‘An exploratory study of an early stage R&D-intensive firm under financialization,’ (with C Haslam), (2010), Accounting Forum, 34, 1, 54-65.

‘A case study of financialization and EVA©’, (with N Cornelius), Critical Perspectives on Accounting, (2008), 19, 8, 1219-123.

SELECTED BOOK CHAPTER

‘La conduite de soi et les sujets entreprenants: les cas Midco et Techco’ (with N Cornelius) in E Pezet (ed.) (2007) ‘Conduite de soi et management. Enquete sur les asceses de la performance,’ Soutien de l’association française de gestion des resources humaines (AGRH), Paris Vuibert, pp. 129-152.

SELECTED REPORT

‘UK bio-pharma: innovation, re-invention and capital at risk’ (2011) (Haslam, C., Tsitsianis, N.& Gleadle, P.), The Institute of Chartered Accountants of Scotland (ICAS). ISBN 978-1-904574-79-8.
The Department for Business, Innovation & Skills Strategy for UK Life Sciences document (December 2011) adopted several of the recommendations made including sponsoring open innovation models and providing £180million over the next three years in a catalyst fund.